Paul Jeffrey to Adult
This is a "connection" page, showing publications Paul Jeffrey has written about Adult.
Connection Strength
0.236
-
Garcia MM, Lenz K, Greenwood BC, Angelini MC, Thompson T, Clements KM, Mauro RP, Jeffrey PL. Impact of Sequential Opioid Dose Reduction Interventions in a State Medicaid Program Between 2002 and 2017. J Pain. 2019 08; 20(8):876-884.
Score: 0.049
-
Kouris G, Hydery T, Greenwood BC, Lavitas P, Price M, Clements K, Alper CJ, Lenz K, Jeffrey PL. Effectiveness of Ledipasvir/Sofosbuvir and Predictors of Treatment Failure in Members with Hepatitis C Genotype 1 Infection: A Retrospective Cohort Study in a Medicaid Population. J Manag Care Spec Pharm. 2018 Jul; 24(7):591-597.
Score: 0.047
-
Hydery T, Price MK, Greenwood BC, Takeshita M, Kunte PS, Mauro RP, Lenz K, Jeffrey PL. Evaluation of Progesterone Utilization and Birth Outcomes in a State Medicaid Plan. Pharmacotherapy. 2017 Oct; 37(10):1328-1334.
Score: 0.044
-
Tran S, Lavitas P, Stevens K, Greenwood BC, Clements K, Alper CJ, Lenz K, Price M, Hydery T, Arnold JL, Takeshita M, Bacon R, Peristere JP, Jeffrey PL. The Effect of a Federal Controlled Substance Act Schedule Change on Hydrocodone Combination Products Claims in a Medicaid Population. J Manag Care Spec Pharm. 2017 May; 23(5):532-539.
Score: 0.043
-
Clements KM, Clark RE, Lavitas P, Kunte P, Graham CS, O'Connell E, Lenz K, Jeffrey P. Access to New Medications for Hepatitis C for Medicaid Members: A Retrospective Cohort Study. J Manag Care Spec Pharm. 2016 Jun; 22(6):714-722b.
Score: 0.041
-
Tesell MA, Alper CJ, Bacon R, Greenwood BC, Lenz K, Jeffrey PL, Stevens K. Effect of Lumacaftor/Ivacaftor on Pulmonary Exacerbation Rates in Members with Cystic Fibrosis in a Medicaid Population. J Manag Care Spec Pharm. 2019 Sep; 25(9):1021-1025.
Score: 0.013